NCT01404000

Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal

Phase II Study Exploring Efficacy and Safety of Iodinated Activated Charcoal in COPD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: PharmaLundensis AB · Industry
• Sex: All
• Age: 45 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study s to determine whether treatment with Iodinated Active Charcoal can improve lung function and physical capacity in patients with chronic obstructive lung disorders. The rational for the study is the observation that COPD patients have an increased tissue load of mercury interfering with the function by NeuroEpithelial Endocrine (NEE) cells in the respiratory tract. Mercury binding to these NEE cells leads to an increased smooth muscle tonus and a reduced response to bronchodilator treatment. Initial observational data have shown an improved lung function and improved functional capacity after treatment motivating a larger placebo controlled POC study

Conditions

• Chronic Obstructive Lung Disease

Interventions

Type	Name	Description
DRUG	Iodinated Active Charcoal (IodoCarb)	3 g will be given as an oral suspension once daily for 56 days

Timeline

• Start date: 2011-11-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2011-07-27
• Last updated: 2013-11-15

Locations

1 site across 1 country: Sweden